Side effects, including inflammation and cachexia, have been recorded after systemic administration, which were severe enough to terminate phase II/III clinical trials with CNTF in ALS patients [56,57,66,67,68,69] (Figure 2). The gene discussed is CNTF; the disease is amyotrophic lateral sclerosis.